Houston Zoo Partners with BlueSprig to Enhance Inclusivity for Families with Autism
30 oct. 2024 11h09 HE
|
BlueSprig Pediatrics, Inc.
HOUSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking initiative aimed at fostering inclusivity, the Houston Zoo has partnered with BlueSprig Pediatrics, Inc. (BlueSprig) to create a more...
BlueSprig Sponsors Armani Williams, the First Professional Driver in NASCAR Openly Diagnosed with Autism Spectrum Disorder
22 oct. 2024 10h21 HE
|
BlueSprig Pediatrics, Inc.
MIAMI, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BlueSprig Pediatrics, Inc. (BlueSprig), a leading provider of Applied Behavior Analysis (ABA) therapy services for children with autism, today announces it...
Lighthouse Autism Center Announces Expansion of ABA Services in Iowa
24 sept. 2024 09h00 HE
|
Lighthouse Autism Center
Lighthouse Autism Center is expanding its ABA services with a new center in Cedar Rapids, IA, set to open in late 2024. This will be their sixth IA center.
VR Helps Children with Autism Develop Social, Communication Skills, New Research Shows
23 sept. 2024 09h00 HE
|
BlueSprig Pediatrics, Inc.
HOUSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BlueSprig Pediatrics, Inc. (BlueSprig), a leader in Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum Disorder (ASD),...
Key Highlights of Lighthouse Fusion
27 août 2024 09h00 HE
|
Lighthouse Autism Center
Lighthouse Autism Center expands its speech therapy program with more dually certified SLPs and BCBAs, offering better outcomes for children with autism.
Lighthouse Autism Center Partners with Local Government Officials to Highlight Autism Services and Community Impact
16 août 2024 09h00 HE
|
Lighthouse Autism Center
Lighthouse Autism Center partners with local officials to boost autism awareness and support, with visits in several cities to highlight services.
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
30 juil. 2024 08h05 HE
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals announces positive topline results from Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
09 juil. 2024 07h00 HE
|
STALICLA
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
Transforming Children's Lives: DP World's Aviv Clinics Dubai’s Revolutionary Youth Protocol
07 juil. 2024 21h00 HE
|
Aviv Clinics
DUBAI, United Arab Emirates, July 07, 2024 (GLOBE NEWSWIRE) -- At DP World's Aviv Clinics Dubai, the world’s most advanced brain and body performance clinic, we understand the heartache parents feel...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
27 juin 2024 07h10 HE
|
STALICLA
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core...